Insights & Perspectives

Filter by














Therapeutic Area / Research

Search Insights:
Showing 1 to 10 of 378
Filter by: Unfiltered

White Paper | Jul 22, 2019

What Behavioral Science can teach us about communications research

Read more | | Share

Case Study | Jul 17, 2019

Overcoming Barriers to Change

Read more | | Share

Case Study | Jul 17, 2019

Capturing Hearts and Minds

Read more | | Share

Article | Jul 16, 2019

Three Key Questions About Adherence/Compliance in 2019

Read more | | Share

White Paper | Jul 15, 2019

Interpreter of Maladies

Read more | | Share

Case Study | Jun 26, 2019

Overcoming Barriers at Both the Market and Brand Level

In order to optimize commercial opportunities and overcome barriers at both the market and brand level, companies must develop effective brand strategies for product differentiation to ultimately drive brand growth.

Read more | | Share

Blog Post | Jun 17, 2019

Immersion Delivers Fresh Insights and Business Opportunities

"Change the way you look at things and the things you look at change".

Read more | | Share

Article | Jun 4, 2019

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019.

Read more | | Share

Article | Jun 4, 2019

ASCO 2019 – phase I data generates hope for the future

Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS inhibitor AMG 510. Arnold DuBell, a senior consultant at Kantar, discusses further.

Read more | | Share

Article | Jun 3, 2019

ASCO 2019 – Enfortumab comes out fighting in bladder cancer

At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastatic bladder cancer. The data presented were from Cohort 1 of the trial, which evaluated enfortumab in relapsed patients who had been treated with a platinum and a checkpoint inhibitor. Kantar’s Len Kusdra reviewed the study.

Read more | | Share
Page  < 12345678910 >